MMS

Call Directions Website

MMS is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach.

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical, biotech, and medical device industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating, and the company has been recognized as a leading CRO in Global Health & Pharma’s international awards programs for three consecutive years.

10/29/2026

MMS is heading to OCT DACH in Zurich, November 3–4, where Lucy Sutton, Vice President of European Business Development, will be connecting with leaders across the clinical development community.

From regulatory strategy and medical writing to biometrics, data management, pharmacovigilance, and regulatory operations, MMS brings together specialist expertise to support complex development programs from strategy through ex*****on.

Book a meeting with Lucy to discuss your development priorities, current challenges, and how MMS’s integrated expertise can support your program: https://hubs.li/Q04C8JfW0

10/28/2026

MMS is heading to CNS Summit in Boston, November 1–4, where Amanda Beaster, Senior Director of Regulatory Strategy, will present“Standardized MedDRA Coding for Psychedelic and Related Therapies: A Framework for Labeling and Consistent Safety Reporting.”

Visit Poster 25, to explore a framework for more standardized labeling and consistent safety reporting in psychedelic and related therapies.

Amanda will be joined at the summit by Chris Schoonmaker, Chief Operating Officer, and Duane Robinson, Senior Director of Business Development.

Book a meeting with the MMS team for an insightful discussion on CNS drug development, regulatory strategy, and the evolving considerations surrounding psychedelic therapies: https://hubs.li/Q04C8C8W0

10/27/2026

Clinical data contains answers that can inform critical study decisions. But getting to those answers can mean specialist support, custom outputs, and time-consuming back-and-forth.

Ask the Data, an AI-driven capability within Datacise®, helps change that.

Study teams can ask questions directly in plain English, explore the relevant data, and move more quickly from question to decision-ready insight, with transparency into the assumptions and logic behind each answer.

Watch the video to see Ask the Data in action.

10/27/2026

Recent proposals in both China and the US are bringing new scrutiny to cross-border technology transfer and investment in biotechnology. China has proposed new controls covering advanced biopharmaceutical technologies, while the US Treasury has proposed expanding outbound investment restrictions to biotechnology.

Against that backdrop, the fundamentals remain compelling. China-based biotechs accounted for nearly 30% of the global drug-development pipeline by Q1 2026, with more than 1,200 novel candidates in clinical trials.

In our latest blog, Ben Dudley, President and Chief Commercial Officer at MMS, explores what this evolving environment means for global biopharma and what teams need to consider when taking China-originated assets into US and global development.

From regulatory strategy and data readiness to biostatistics and CMC, getting the development pathway right early can make a material difference.

Read the blog: https://hubs.li/Q04CrNm10

10/26/2026

Safety Review Committees (SRCs) and Data Monitoring Committees (DMCs) are making increasingly complex decisions, yet many review processes still rely on static reports that can limit insight and slow decision-making. In this webinar, MMS experts will explore how interactive safety visualizations can help reviewers investigate emerging signals in real time, access participant-level data, and make more informed safety decisions.

Register today to join an insightful discussion with Chris Schoonmaker, Chief Operating Officer, Kris Wenzel, Director, Data Science, and Andrew Mills, Strategic Principal Statistician: https://hubs.li/Q04C7f1c0

10/26/2026

MMS is heading to OCT New England!

Sandy Robbins, Vice President, Commercial Operations, and Amanda Sullivan, Director, Business Development, will be in Boston on October 27–28, 2026, connecting with the clinical development community.

Attending? Book a meeting with the team to discuss your development priorities and learn how MMS can help move your programs forward: https://hubs.li/Q04Cg4kY0

10/23/2026

Earlier detection could reshape the future of Alzheimer’s drug development.

As the field moves toward more targeted, biomarker-driven approaches, tau imaging is becoming increasingly important for understanding disease progression, informing patient selection, and supporting treatment decisions.

In our latest blog, Ben Kaspar, Vice President, Regulatory Strategy, explores what the approval of TAUKLARIFY™ could signal for the evolving role of tau imaging and the evidentiary frameworks used in Alzheimer’s diagnostic development.

Read the blog to explore what these developments could mean for the next generation of Alzheimer’s therapies and diagnostics: https://hubs.li/Q04B_rD50

You can now listen to our latest blogs, with audio versions available alongside the full articles.

10/21/2026

MMS is growing, and so is our global team!

We’re hiring across the US, UK, and India, with opportunities spanning pharmacovigilance, medical and regulatory writing, biometrics, technology, and more.

US:
• Senior Pharmacovigilance Physician
• Proposal Development Manager
• Senior Post-Market Pharmacovigilance Specialist
• Study Design Statistician

US & UK:
• Senior Medical Writer
• Senior Nonclinical Writer
• Senior Manager, Regulatory and Medical Writing

India:
• Senior Software QA Tester
• Senior Medical Reviewer

Ready for your next opportunity? Join MMS and explore our open roles:
https://hubs.li/Q04BV1cY0

10/20/2026

How can we bring greater consistency to safety reporting for psychedelic and related therapies?

At CNS Summit 2026 in Boston, November 1–4, Amanda Beaster, PhD, Senior Director, Regulatory Strategy at MMS, will present research on standardized MedDRA coding and its role in supporting more consistent adverse event reporting, safety monitoring, and regulatory decision-making.

Amanda will be joined by Chris Schoonmaker, Chief Operating Officer, and Duane Robinson, Senior Director, Business Development.

Book a meeting with the MMS team at CNS Summit to learn more: https://hubs.li/Q04Bx-r40

Address

6880 Commerce Boulevard
Canton, MI
48187

Telephone

+17342450310

Website

http://www.mmsholdings.com/

Alerts

Be the first to know and let us send you an email when MMS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.